Loading chat...
WV HB4610
Bill
Status
Enrolled
3/14/2026
Primary Sponsor
Michael Hornby
Click for details
AI Summary
- Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational drugs, biological products, or devices (including gene therapy and neoantigen vaccines) that are custom-made based on their genetic profile
- Requires eligible patients to have considered all FDA-approved treatments, received a physician recommendation, and provided written informed consent documenting understanding of risks, potential outcomes, and financial liability
- Protects healthcare providers from disciplinary action or loss of Medicare certification solely for recommending individualized investigational treatments to eligible patients
- Prohibits private lawsuits against manufacturers or caregivers for harm caused by individualized treatments, provided they made good-faith compliance efforts and exercised reasonable care
- Heirs of patients who die during treatment are not liable for outstanding debts related to the individualized treatment, and the law takes effect January 1, 2027
Legislative Description
Safeguard the Right-To-Try Cutting-Edge Medicine Act
Health
Last Action
Completed legislative action
3/14/2026
Committee Referrals
Judiciary3/4/2026
Health and Human Resources1/30/2026
Health & Human Resources1/20/2026
Full Bill Text
No bill text available